Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
Dermata Therapeutics has successfully completed its initial public offering, closing on the sale of 2,571,428 shares of common stock and accompanying warrants at $7.00 per share, raising approximately $18 million. The company intends to utilize the proceeds to further develop its clinical products, including DMT310 and DMT410, targeting conditions such as rosacea, psoriasis, and aesthetic indications. The offering included an option for underwriters to purchase additional shares, which has been partially exercised. Shares began trading on the Nasdaq under the symbols DRMA and DRMAW.
- Raised approximately $18 million through IPO to advance clinical development.
- Intends to use funds for clinical development of products targeting significant skin conditions.
- Opportunity for further funding with underwriters' option to purchase additional shares.
- Potential dilution of shares due to additional shares being offered.
- -
SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying, developing and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases and conditions, today announced the closing of its previously announced initial public offering of 2,571,428 shares of its common stock and accompanying warrants to purchase up to 2,571,428 shares of common stock. Each share of common stock was sold together with one warrant to purchase one share of common stock with an exercise price of
The shares of common stock and warrants began trading on the Nasdaq Capital Market on August 13, 2021, under the symbols "DRMA" and "DRMAW," respectively.
The Company intends to use substantially all of the net proceeds from the offering to advance the clinical development of DMT310 for the treatment of rosacea and psoriasis, to advance the clinical development of DMT410 for the treatment of various aesthetic indications, to fund its planned non-clinical trials and the pharmacokinetic study for its DMT310 program, for manufacturing drug product for its clinical trials in acne, rosacea and psoriasis, for a payment to a licensor, and for working capital and other general corporate purposes.
Maxim Group LLC acted as the sole book-running manager and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as a co-manager in connection with the offering.
A registration statement on Form S-1 (File Nos. 333-256997 and 333-258772) was filed with the Securities and Exchange Commission ("SEC"), which became effective on August 12, 2021. A final prospectus relating to the offering was filed with the SEC and is available on the SEC's website at http://www.sec.gov. The offering was made only by means of a prospectus forming part of the effective registration statement. Electronic copies of the prospectus relating to this offering may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, at (212) 895-3745. Before investing in this offering, interested parties should read in its entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dermata Therapeutics
Dermata is a clinical-stage dermatology company focused on identifying, developing and commercializing innovative pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases and conditions the Company believe represent significant market opportunities because current therapies are inadequate or non-existent. For more information, please visit www.dermatarx.com.
Forward Looking Statements
This press release contains certain forward-looking statements, including those relating to the regarding the use of proceeds and other statements that are predictive in nature. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended from time to time, under the caption 'Risk Factors.'
Contact:
Sean Proehl
Investor Relations
(858) 800-2543 Ext. 705
SOURCE: Dermata Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/660219/DermataTherapeutics-IncAnnounces-Closing-of-Upsized-180-Million-Initial-Public-Offering
FAQ
What is the purpose of Dermata Therapeutics' IPO?
How much money did Dermata Therapeutics raise in its IPO?
What are the stock symbols for Dermata Therapeutics?
What additional options do underwriters have in this offering?
